Evidence map›Paper›PMID 37991349›Full record

ArticleInfection and immunity2023

Efficacy of a

Dina A Moustafa, Antonio DiGiandomenico, Vishnu Raghuram, Marc Schulman, Jennifer M Scarff, Michael R Davis, John J Varga, Charles R Dean, Joanna B Goldberg

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Infection and immunity, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.8field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. International journal of molecular sciences · 2025
    Review
  5. Review
  6. Article
  7. Mucin adhesion of serial cystic fibrosis airwaysFrontiers in cellular and infection microbiology · 2024
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Dina A MoustafaDepartment of Pediatrics, Division of Pulmonary, Asthma, Cystic Fibrosis, and Sleep, Emory University School of Medicine, Atlanta, Georgia, USA.ORCID 0000-0002-9616-5947
Antonio DiGiandomenicoDepartment of Microbiology, Immunology, and Cancer Biology, University of Virginia Health System, Charlottesville, Virginia, USA.ORCID 0000-0003-1745-647X
Vishnu RaghuramMicrobiology and Molecular Genetics Program, Graduate Division of Biological and Biomedical Sciences, Laney Graduate School, Emory University, Atlanta, Georgia, USA.
Marc SchulmanDepartment of Microbiology, Immunology, and Cancer Biology, University of Virginia Health System, Charlottesville, Virginia, USA.
Jennifer M ScarffDepartment of Microbiology, Immunology, and Cancer Biology, University of Virginia Health System, Charlottesville, Virginia, USA.
Michael R DavisDepartment of Microbiology, Immunology, and Cancer Biology, University of Virginia Health System, Charlottesville, Virginia, USA.
John J VargaDepartment of Pediatrics, Division of Pulmonary, Asthma, Cystic Fibrosis, and Sleep, Emory University School of Medicine, Atlanta, Georgia, USA.
Charles R DeanDepartment of Microbiology, Immunology, and Cancer Biology, University of Virginia Health System, Charlottesville, Virginia, USA.
Joanna B GoldbergDepartment of Pediatrics, Division of Pulmonary, Asthma, Cystic Fibrosis, and Sleep, Emory University School of Medicine, Atlanta, Georgia, USA.ORCID 0000-0002-5285-5188
University of Virginia Health System · USEmory University · US

Funding

Live Attenuated Recombinant Bacterial Delivery of Polysaccharide Vaccine AntigensR01AI068112 · NIAID · UNIVERSITY OF VIRGINIA · PI GOLDBERG, JOANNA B · 2006 to 2010
$2.0M
Synthesis of P.Aeruginosa LPS and its Role in InfectionR01AI050230 · NIAID · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI GOLDBERG, JOANNA B. · 2001 to 2004
$936k
Pseudomonas aeruginasa LPS: A Post-Genomic AnalysisR21AI053842 · NIAID · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI GOLDBERG, JOANNA B. · 2003 to 2004
$456k
NIAID NIH HHS R01 AI050230NIAID NIH HHS R01 AI068112NIAID NIH HHS R21 AI053842
6 · The paper itself

Abstract

There are currently no approved vaccines against the opportunistic pathogen

Indexed as

O AntigensPseudomonas InfectionsAnimalsAntibodies, BacterialBacterial VaccinesLipopolysaccharidesMicePseudomonas aeruginosaSerogroupAntibodies, BacterialBacterial VaccinesLipopolysaccharidesO Antigensacute pneumonialipopolysaccharidemucosal vaccinesPseudomonas aeruginosa

Identifiers

PMID37991349
PMCPMC10715167
OpenAlexW4388901831

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.